GlobeNewswire Inc.··Sanofi And RegeneronDupixent Wins FDA Nod for Young Children With Chronic Urticaria, Expanding Market Reach
FDA approves Dupixent for children ages 2-11 with uncontrolled chronic spontaneous urticaria, marking first biologic treatment for this pediatric population.
SNYREGNchronic spontaneous urticariaFDA approval